Education
About Us
Working with TipRanks
Follow Us
KalVista Pharmaceuticals (KALV)
NASDAQ:KALV
KALV Stock Chart & Stats
$11.13
-$0.39(-4.51%)
At close: 4:00 PM EST
$11.13
-$0.39(-4.51%)
Day’s Range― - ―
52-Week Range$7.30 - $17.28
Previous CloseN/A
Volume49.40K
Average Volume (3M)1.30M
Market Cap
$562.32M
Enterprise Value$676.16M
Total Cash (Recent Filing)$191.47M
Total Debt (Recent Filing)$6.14M
Price to Earnings (P/E)―
Beta1.05
Next Earnings
Dec 04, 2025EPS Estimate
-1.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.12
Shares Outstanding50,523,273
10 Day Avg. Volume1,058,107
30 Day Avg. Volume1,296,801
Financial Highlights & Ratios
PEG Ratio-0.51
Price to Book (P/B)7.17
Price to Sales (P/S)0.00
P/FCF Ratio-4.47
Enterprise Value/Market Cap1.20
Enterprise Value/Revenue474.17
Enterprise Value/Gross Profit637.89
Enterprise Value/Ebitda-3.59
Forecast
1Y Price Target
$28.43Price Target Upside155.44% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
Bulls Say, Bears Say
Bulls Say
Market PenetrationEkterly is well positioned as the first oral on-demand option for HAE, expected to broaden and quickly penetrate the market.
Product LaunchEarly US uptake confirms broad patient and physician enthusiasm and validates management's pre-launch investment in commercial infrastructure.
Sales PerformanceEkterly numbers are better than expected, generating $1.4mn sales by the end of July, which is twice the forecasted amount by several analysts.
Bears Say
KalVista Pharmaceuticals News
KALV FAQ
What was KalVista Pharmaceuticals’s price range in the past 12 months?
KalVista Pharmaceuticals lowest stock price was $7.30 and its highest was $17.28 in the past 12 months.
What is KalVista Pharmaceuticals’s market cap?
KalVista Pharmaceuticals’s market cap is $562.32M.
When is KalVista Pharmaceuticals’s upcoming earnings report date?
KalVista Pharmaceuticals’s upcoming earnings report date is Dec 04, 2025 which is in 37 days.
How were KalVista Pharmaceuticals’s earnings last quarter?
KalVista Pharmaceuticals released its earnings results on Sep 11, 2025. The company reported -$1.12 earnings per share for the quarter, missing the consensus estimate of -$0.953 by -$0.167.
Is KalVista Pharmaceuticals overvalued?
According to Wall Street analysts KalVista Pharmaceuticals’s price is currently Undervalued.
Does KalVista Pharmaceuticals pay dividends?
KalVista Pharmaceuticals does not currently pay dividends.
What is KalVista Pharmaceuticals’s EPS estimate?
KalVista Pharmaceuticals’s EPS estimate is -1.03.
How many shares outstanding does KalVista Pharmaceuticals have?
KalVista Pharmaceuticals has 50,523,273 shares outstanding.
What happened to KalVista Pharmaceuticals’s price movement after its last earnings report?
KalVista Pharmaceuticals reported an EPS of -$1.12 in its last earnings report, missing expectations of -$0.953. Following the earnings report the stock price went down -3.769%.
Which hedge fund is a major shareholder of KalVista Pharmaceuticals?
Currently, no hedge funds are holding shares in KALV
KalVista Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$28.43 (155.44% Upside)
$28.43 (155.44% Upside)
Blogger Sentiment
Bullish
KALV Sentiment 75%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 303.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.2%
Last 30 Days ▲ 15.8%
Last 30 Days ▲ 15.8%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-7.78%
12-Months-Change
Fundamentals
Return on Equity
-190.18%
Trailing 12-Months
Asset Growth
7.65%
Trailing 12-Months
Company Description
KalVista Pharmaceuticals
KalVista Pharmaceuticals (KALV) is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet needs. Operating primarily in the biotechnology sector, KalVista is dedicated to developing treatments for hereditary angioedema (HAE) and other plasma kallikrein-related diseases. The company's lead product candidate, sebetralstat, is being developed as a potential oral on-demand treatment for HAE attacks.
KALV Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected a generally positive sentiment, highlighting significant achievements such as the FDA approval and successful early launch of EKTERLY, strong patient and prescriber engagement, and positive regulatory progress in Europe. However, challenges remain with high operating expenses and potential reimbursement hurdles with certain insurers.View all KALV earnings summariesKALV Stock 12 Month Forecast
Average Price Target
$28.43
▲(155.44% Upside)
Technical Analysis
Savara
―
Arvinas Holding Company
―
Gossamer Bio
―
Compass Therapeutics
―
Bicara Therapeutics Inc.
―
Ownership Overview
11.85% Insiders
14.85% Mutual Funds
<0.01% Other Institutional Investors
62.71% Public Companies and Individual Investors